We are live on ! Find out more
KPRX icon

Kiora Pharmaceuticals
KPRX

16 hedge funds and large institutions have $19M invested in Kiora Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

104% more capital invested

Capital invested by funds: $9.31M → $19M (+$9.68M)

33% more funds holding

Funds holding: 12 → 16 (+4)

0.04% more ownership

Funds ownership: 0.11% → 0.15% (+0.04%)

Holders
16
Holders Change
+4
Holders Change %
+33.33%
% of All Funds
0.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
4
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$9.27M
2
Renaissance Technologies
Renaissance Technologies
New York
+$887K
3
PHP
Parkman Healthcare Partners
Connecticut
+$456K
4
Two Sigma Advisers
Two Sigma Advisers
New York
+$392K
5
Two Sigma Investments
Two Sigma Investments
New York
+$320K

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$2K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$16.7M +$9.27M +4,253 +84%
Renaissance Technologies
2
Renaissance Technologies
New York
$730K +$887K +407 New
PHP
3
Parkman Healthcare Partners
Connecticut
$375K +$456K +209 New
Two Sigma Advisers
4
Two Sigma Advisers
New York
$323K +$392K +180 New
Two Sigma Investments
5
Two Sigma Investments
New York
$263K +$320K +147 New
Vanguard Group
6
Vanguard Group
Pennsylvania
$217K +$122K +56 +86%
BlackRock
7
BlackRock
New York
$130K – – –
Citadel Advisors
8
Citadel Advisors
Florida
$100K +$122K +56 New
Geode Capital Management
9
Geode Capital Management
Massachusetts
$73K +$13.1K +6 +17%
ECM
10
ExodusPoint Capital Management
New York
$62K +$76.3K +35 New
UBS Group
11
UBS Group
Switzerland
$21K +$2.18K +1 +9%
US Bancorp
12
US Bancorp
Minnesota
$13K – – –
Royal Bank of Canada
13
Royal Bank of Canada
Ontario, Canada
$8K – – –
SFP
14
Sterling Financial Planning
New Jersey
$6K – – –
Morgan Stanley
15
Morgan Stanley
New York
$2K – – –
Osaic Holdings
16
Osaic Holdings
Arizona
$2K – – –
TRCT
17
Tower Research Capital (TRC)
New York
– -$2K -1 Closed

KPRX Hedge Fund Activity: Q1 2021 in Review

16 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q1 2021, worth a combined $19M — up 104% from $9.31M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new KPRX positions and 1 closed out — a net gain of 5 holders — while 4 added to existing stakes and 0 trimmed.

The largest buyer was Armistice Capital, adding an estimated $9.27M. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $2K sold.

  • 16 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q1 2021, up from 12 in Q4 2020.
  • Funds reported $19M of Kiora Pharmaceuticals stock for Q1 2021, up 104% quarter-over-quarter.
  • 6 funds opened new Kiora Pharmaceuticals positions in Q1 2021 and 1 closed out, a net change of +5 holders.
  • The largest Kiora Pharmaceuticals buyer in Q1 2021 was Armistice Capital, an estimated $9.27M added.
  • The largest Kiora Pharmaceuticals seller in Q1 2021 was Tower Research Capital (TRC), an estimated $2K sold.

Based on aggregated 13F filings for Q1 2021.